Drug intelligence / Profile preview

tragacanth + ctenocephalides felis + ctenocephalides canis + karaya gum + acacia

Development stage: Approved
Lead developer: Jubilant HollisterStier
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

This product is a **multi-allergen extract immunotherapy** consisting of tragacanth, **Ctenocephalides felis** extract, **Ctenocephalides canis** extract, karaya gum, and acacia, formulated as an injectable allergenic extract solution for human use. It is used in allergy practice for **diagnostic testing and allergen-specific immunotherapy (hyposensitization)** in patients with demonstrated sensitivity to the included allergens, with administration by deep subcutaneous injection under specialist supervision because of the risk of severe systemic allergic reactions. Publicly accessible NDC/RxNorm-linked listings support the existence of this exact combination product and place it within the longstanding U.S. allergenic extract category marketed under the 36987 labeler prefix associated with HollisterStier/Nelco allergen products. The therapeutic concept is desensitization of an **IgE-mediated allergic response** through controlled repeated exposure to relevant allergen extracts.

Other names: tragacanth gum + cat flea extract + dog flea extract + karaya gum + arabic gumtragacanth + cat flea + dog flea + karaya gum + acaciaallergenic extract combination of tragacanth + ctenocephalides felis + ctenocephalides canis + karaya gum + acacia

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on tragacanth + ctenocephalides felis + ctenocephalides canis + karaya gum + acacia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tragacanth + ctenocephalides felis + ctenocephalides canis + karaya gum + acacia.

Explore the full profile